Skip to Main content Skip to Navigation
Journal articles

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

Abstract : Background Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. Objectives To utilize data collected in a French investigator-initiated, phase III, open-label, randomized controlled trial to demonstrate the efficacy and safety of rituximab and seek approval for its use in PV.
Complete list of metadata

https://hal.univ-reims.fr/hal-03434482
Contributor : Arnaud Pommier Connect in order to contact the contributor
Submitted on : Thursday, November 18, 2021 - 12:03:42 PM
Last modification on : Tuesday, December 7, 2021 - 3:16:59 AM
Long-term archiving on: : Saturday, February 19, 2022 - 6:53:15 PM

File

BJD-182-1111.pdf
Publisher files allowed on an open archive

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Collections

Citation

D Chen, A Odueyungbo, E Csinady, L Gearhart, P Lehane, et al.. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect. British Journal of Dermatology, Wiley, 2019, 182, pp.1111 - 1119. ⟨10.1111/bjd.18482⟩. ⟨hal-03434482⟩

Share

Metrics

Record views

10

Files downloads

21